Tower Research Capital (TRC)’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Tower Research Capital (TRC)’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-88	Closed	-$2K	–	6204
2022 Q2	$2K	Buy	+88	New	+$2.33K	﹤0.01%	5539
2021 Q2	–	Sell	-177	Closed	-$5K	–	5588
2021 Q1	$5K	Buy	+177	New	+$4.64K	﹤0.01%	4664
2020 Q4	–	Sell	-42	Closed	-$1K	–	5219
2020 Q3	$1K	Buy	+42	New	+$1.01K	﹤0.01%	4694
2018 Q2	–	Sell	-46	Closed	-$1K	–	3793
2018 Q1	$1K	Buy	+46	New	+$1.01K	﹤0.01%	3065

Other funds holding FTXH

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

IAN

Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

KNW

Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tower Research Capital (TRC)'s FTXH Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2022, closing a stake of 88 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in FTXH in Q1 2018 and held it in 4 quarters. The position peaked at $5K in Q1 2021. 26 funds tracked by Wall St. Rank hold FTXH as of Q3 2022.

Tower Research Capital (TRC) reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q3 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 88 First Trust Nasdaq Pharmaceuticals ETF shares in Q3 2022, an estimated $2K.
Tower Research Capital (TRC) first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2018 and held it in 4 quarters.
Tower Research Capital (TRC)'s First Trust Nasdaq Pharmaceuticals ETF position peaked at $5K in Q1 2021.
26 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.